Print

Verastem, Inc. (VSTM) Reports Data on Focal Adhesion Kinase Program at the 2012 European Organization for Research and Treatment of Cancer Symposium on Molecular Targets and Cancer Therapeutics  
11/9/2012 11:01:27 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported new data from its focal adhesion kinase (FAK) inhibition program and commented on encouraging clinical data on FAK inhibition presented at the 2012 EORTC Symposium on Molecular Targets and Cancer Therapeutics being held in Dublin, Ireland.
//-->